While DNA damage, such as radiation therapy, is the focus of this mini-review, the impact of other novel agents, such as tyrosine kinase inhibitors, agents targeting EWSR1::FLI1, etc., on the Ewing sarcoma TIME are also worthy of exploration and represent a limitation of this mini-review. Here, EWSR1 is linked to Ewing sarcoma.